Cargando…

Pathological expression of tissue factor confers promising antitumor response to a novel therapeutic antibody SC1 in triple negative breast cancer and pancreatic adenocarcinoma

The pathological presence of tissue factor (TF) in cancer cells promotes tumor-initiated thrombosis and cancer metastasis. We found that TF is aberrantly present in large percentage of aggressive triple negative breast cancer (TNBC) and pancreatic adenocarcinoma (PaC), two most lethal forms of malig...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuesai, Li, Qingrou, Zhao, Hui, Ma, Lanping, Meng, Tao, Qian, Jianchang, Jin, Rui, Shen, Jingkang, Yu, Ker
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5601716/ https://www.ncbi.nlm.nih.gov/pubmed/28938620 http://dx.doi.org/10.18632/oncotarget.19175

Ejemplares similares

mTOR Promotes Tissue Factor Expression and Activity in EGFR-Mutant Cancer
por: Cong, Ying, et al.
Publicado: (2020)

Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer
por: Qian, Jianchang, et al.
Publicado: (2016)

Antitumor activity of new chemical compounds in triple negative mammary adenocarcinoma models
por: Giolito, María V, et al.
Publicado: (2020)

mTOR complex-2 stimulates acetyl-CoA and de novo lipogenesis through ATP citrate lyase in HER2/PIK3CA-hyperactive breast cancer
por: Chen, Yaqing, et al.
Publicado: (2016)

The nature of triple-negative breast cancer classification and antitumoral strategies
por: Kim, Songmi, et al.
Publicado: (2020)

The clinical promise of immunotherapy in triple-negative breast cancer
por: Vikas, Praveen, et al.
Publicado: (2018)

Antitumor Activity of Noscapine in Combination with Doxorubicin in Triple Negative Breast Cancer
por: Chougule, Mahavir B., et al.
Publicado: (2011)

Molecular Targets and Promising Therapeutics of Triple-Negative Breast Cancer
por: Ryu, Won-Ji, et al.
Publicado: (2021)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer
por: Owusu-Brackett, Nicci, et al.
Publicado: (2019)

Triple-negative breast cancer: promising prognostic biomarkers currently in development
por: Sukumar, Jasmine, et al.
Publicado: (2021)

Cry1Ac Protoxin Confers Antitumor Adjuvant Effect in a Triple-Negative Breast Cancer Mouse Model by Improving Tumor Immunity
por: Servin-Garrido, Roberto Raúl, et al.
Publicado: (2022)

Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas
por: Bokas, Alexandros, et al.
Publicado: (2020)

Artificial intelligence for early detection of pancreatic adenocarcinoma: The future is promising
por: Mendoza Ladd, Antonio, et al.
Publicado: (2021)

Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells
por: Tanei, Tomonori, et al.
Publicado: (2016)

Antitumoral and antimetastatic activity of Maitake D-Fraction in triple-negative breast cancer cells
por: Alonso, Eliana Noelia, et al.
Publicado: (2018)

Fabrication of Ginsenoside-Based Nanodrugs for Enhanced Antitumor Efficacy on Triple-Negative Breast Cancer
por: Zuo, Shuting, et al.
Publicado: (2022)

Nicotinic receptors modulate antitumor therapy response in triple negative breast cancer cells
por: Español, Alejandro, et al.
Publicado: (2022)

Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
por: Mancini, Patrizia, et al.
Publicado: (2014)

Predictive Biomarkers for Response to Immunotherapy in Triple Negative Breast Cancer: Promises and Challenges
por: Wang, Xiaoxiao, et al.
Publicado: (2023)

Association of HDAC8 Expression with Pathological Findings in Triple Negative and Non-Triple Negative Breast Cancer: Implications for Diagnosis
por: Menbari, Mohammad-Nazir, et al.
Publicado: (2020)

ARNTL2 is a Prognostic Biomarker and Correlates with Immune Cell Infiltration in Triple-Negative Breast Cancer
por: Wang, Xiaoyu, et al.
Publicado: (2021)

Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future
por: Goel, Gaurav, et al.
Publicado: (2015)

Targeting of promising transmembrane proteins for diagnosis and treatment of pancreatic ductal adenocarcinoma
por: Mashayekhi, Vida, et al.
Publicado: (2021)

Yiqi Formula Enhances the Antitumor Effects of Erlotinib for Treatment of Triple-Negative Breast Cancer Xenografts
por: Liao, Ming-juan, et al.
Publicado: (2014)

Antitumor activity of the novel multi-kinase inhibitor EC-70124 in triple negative breast cancer
por: Cuenca-López, María Dolores, et al.
Publicado: (2015)

Antitumor efficacy of the Runx2-dendritic cell vaccine in triple-negative breast cancer in vitro
por: Tang, Mi, et al.
Publicado: (2018)

Potent antitumor activity of cepharanthine against triple-negative breast cancer spheroids compared with tetrandrine
por: Kiyomi, Anna, et al.
Publicado: (2020)

A Screened GPR1 Peptide Exerts Antitumor Effects on Triple-Negative Breast Cancer
por: Huang, Chen, et al.
Publicado: (2020)

Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer
por: Li, Haonan, et al.
Publicado: (2020)

Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer
por: Jian, Dan, et al.
Publicado: (2022)

Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines
por: Xie, Xuemei, et al.
Publicado: (2023)

Importance of triple tumor markers as biomarkers in patients with pancreatic ductal adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
por: Thomas, Remy, et al.
Publicado: (2021)

Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer
por: Mezi, Silvia, et al.
Publicado: (2021)

Oncolytic Urabe mumps virus: A promising virotherapy for triple-negative breast cancer
por: Behrens, Marshall D., et al.
Publicado: (2022)

Clinical significance of pancreatic calcifications: a 15-year single-center observational study
por: Wang, Wei, et al.
Publicado: (2022)

NPC1 Confers Metabolic Flexibility in Triple Negative Breast Cancer
por: O’Neill, Kathleen I., et al.
Publicado: (2022)

Defining the molecular pathology of pancreatic body and tail adenocarcinoma
Publicado: (2018)

Pancreatic Ductal Adenocarcinoma: Molecular Pathology and Predictive Biomarkers
por: Taherian, Mehran, et al.
Publicado: (2022)

Establishing the promising role of novel combination of triple therapeutics delivery using polymeric nanoparticles for Triple negative breast cancer therapy
por: Misra, Ranjita, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6h7ruispe9rs8a3lb628d3qg8f